ANDA 79056, held by Chartwell RX. Alfuzosin Hydrochloride.
As of Nov 22, 2026, ANDA 79056 (Alfuzosin Hydrochloride), held by Chartwell RX, was first approved by FDA on Jul 18, 2011, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 18, 2011 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Alfuzosin Hydrochloride10MG · tablet, extended release;oral | Alfuzosin Hydrochloride | Discontinued |
| Nov 13, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 18, 2011 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters